15 results on '"Ginzburg, Yelena Z."'
Search Results
2. Iron dosing in kidney disease: inconsistency of evidence and clinical practice.
- Author
-
Gaweda, Adam E., Ginzburg, Yelena Z., Chait, Yossi, Germain, Michael J., Aronoff, George R., and Rachmilewitz, Eliezer
- Subjects
- *
KIDNEY diseases , *ERYTHROPOIESIS , *BLOOD transfusion , *DRUG administration , *CLINICAL trials - Abstract
The management of anemia in patients with chronic kidney disease (CKD) is difficult. The availability of erythropoiesis-stimulating agents (ESAs) has increased treatment options for previously transfusion-requiring patients, but the recent evidence of ESA side effects has prompted the search for complementary or alternative approaches. Next to ESA, parenteral iron supplementation is the second main form of anemia treatment. However, as of now, no systematic approach has been proposed to balance the concurrent administration of both agents according to individual patient's needs. Furthermore, the potential risks of excessive iron dosing remain a topic of controversy. How, when and whether to monitor CKD patients for potential iron overload remain to be elucidated. This review addresses the question of risk and benefit of iron administration in CKD, highlights the evidence supporting current practice, provides an overview of standard and potential new markers of iron status and outlines a new pharmacometric approach to physiologically compatible individualized dosing of ESA and iron in CKD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Crosstalk between Iron Metabolism and Erythropoiesis.
- Author
-
Huihui Li and Ginzburg, Yelena Z.
- Subjects
- *
IRON metabolism , *ERYTHROPOIESIS , *HEMOGLOBIN synthesis , *IRON deficiency anemia , *THALASSEMIA , *HEMOCHROMATOSIS - Abstract
Iron metabolism and erythropoiesis are inextricably linked. The majority of iron extracted from circulation daily is used for hemoglobin synthesis. In the last 15 years, major advances have been made in understanding the pathways regulating iron metabolism. Hepcidin is a key regulator of iron absorption and recycling and is itself regulated by erythropoiesis. While several viable candidates have been proposed, elucidating the "erythroid regulator" of hepcidin continues to generate significant experimental activity in the field. Although the mechanism responsible for sensing iron demand for erythropoiesis is still incompletely understood, evaluating diseases in which disordered erythropoiesis and/or iron metabolism are showcased has resulted in a more robust appreciation of potential candidates coordinated erythroid iron demand with regulators of iron supply. We present data drawn from four different conditions-iron deficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditary hemochromatosis-both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores. Greater understanding of the interplay between the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more effective therapies for disorders of iron overload, iron deficiency, and hemoglobin synthesis. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
4. Exogenous iron increases hemoglobin in β–thalassemic mice
- Author
-
Ginzburg, Yelena Z., Rybicki, Anne C., Suzuka, Sandra M., Hall, Charles B., Breuer, William, Cabantchik, Z. Ioav, Bouhassira, Eric E., Fabry, Mary E., and Nagel, Ronald L.
- Subjects
- *
PHYSIOLOGICAL effects of iron , *HEMOGLOBINS , *THALASSEMIA , *LABORATORY mice , *GENETIC mutation , *ERYTHROPOIESIS - Abstract
Objective: β–thalassemia results from β–globin gene mutations that lead to ineffective erythropoiesis, shortened red cell survival, and anemia. Patients with β–thalassemia develop iron overload, despite which, hepcidin levels are low. This suggests that hepcidin regulation in β–thalassemia is more sensitive to factors unrelated to iron state. Our preliminary data demonstrates that Hbbth1/th1 mice, a model of β–thalassemia intermedia, have lower bone marrow iron levels while levels in the liver and spleen are increased; the later account for the increased systemic iron burden in β–thalassemia intermedia. We hypothesized that exogenous iron would improve anemia in β–thalassemia intermedia despite systemic iron overload and further suppress hepcidin secondary to progressive expansion of erythroid precursors. Materials and Methods: We investigate parameters involved in red cell production, precursor apoptosis, parenchymal iron distribution, and hepcidin expression in iron treated Hbbth1/th1 mice. Results: Exogenous iron results in an expansion of erythroid precursors in the liver and spleen, leading to an increase in the number of red cells, reticulocytes, and hemoglobin production. A decrease in hepcidin expression is also observed. Conclusions: These findings demonstrate for the first time that iron results in expansion of extramedullary erythropoiesis, which improves anemia and suggests that expansion of extramedullary erythropoiesis itself results in hepcidin suppression in β–thalassemia intermedia. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
5. Tfr2 suppression benefits β-thalassemic erythropoiesis.
- Author
-
Ginzburg, Yelena Z. and Fleming, Robert E.
- Subjects
- *
TRANSFERRIN receptors , *LIVER cells , *HOMEOSTASIS , *HEMOCHROMATOSIS , *ERYTHROPOIESIS - Abstract
The article focuses on the Transferrin receptors (Tfr2). Topics discussed include highly expressed in hepatocytes, where it participates in the regulation of hepcidin expression to modulate iron homeostasis; a role for Tfr2 in erythroid cells was not initially apparent because murine models and human patients with hemochromatosis type 3 have no obvious abnormalities in erythroid parameters; and the beneficial effect on erythropoiesis in b-thalassemic mice dissipates at 37 weeks posttransplant.
- Published
- 2018
- Full Text
- View/download PDF
6. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
- Author
-
Kremyanskaya, Marina, Kuykendall, Andrew T., Pemmaraju, Naveen, Ritchie, Ellen K., Gotlib, Jason, Gerds, Aaron, Palmer, Jeanne, Pettit, Kristen, Nath, Uttam K., Yacoub, Abdulraheem, Molina, Arturo, Saks, Samuel R., Modi, Nishit B., Valone, Frank H., Khanna, Sarita, Gupta, Suneel, Verstovsek, Srdan, Ginzburg, Yelena Z., and Hoffman, Ronald
- Subjects
- *
POLYCYTHEMIA vera , *POLYCYTHEMIA , *HEPCIDIN , *MYELOPROLIFERATIVE neoplasms , *PATIENT reported outcome measures , *MYELOFIBROSIS - Abstract
BACKGROUND Polycythemia vera is a chronic myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory hormone hepcidin, restricts the availability of iron for erythropoiesis. The safety and efficacy of rusfertide in patients with phlebotomy-dependent polycythemia vera are unknown. METHODS In part 1 of the international, phase 2 REVIVE trial, we enrolled patients in a 28-week dose-finding assessment of rusfertide. Part 2 was a double-blind, randomized withdrawal period in which we assigned patients, in a 1:1 ratio, to receive rusfertide or placebo for 12 weeks. The primary efficacy end point was a response, defined by hematocrit control, absence of phlebotomy, and completion of the trial regimen during part 2. Patient-reported outcomes were assessed by means of the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) patient diary (scores range from 0 to 10, with higher scores indicating greater severity of symptoms). RESULTS Seventy patients were enrolled in part 1 of the trial, and 59 were assigned to receive rusfertide (30 patients) or placebo (29 patients) in part 2. The estimated mean (±SD) number of phlebotomies per year was 8.7±2.9 during the 28 weeks before the first dose of rusfertide and 0.6±1.0 during part 1 (estimated difference, 8.1 phlebotomies per year). The mean maximum hematocrit was 44.5±2.2% during part 1 as compared with 50.0±5.8% during the 28 weeks before the first dose of rusfertide. During part 2, a response was observed in 60% of the patients who received rusfertide as compared with 17% of those who received placebo (P=0.002). Between baseline and the end of part 1, rusfertide treatment was associated with a decrease in individual symptom scores on the MPN-SAF in patients with moderate or severe symptoms at baseline. During parts 1 and 2, grade 3 adverse events occurred in 13% of the patients, and none of the patients had a grade 4 or 5 event. Injection-site reactions of grade 1 or 2 in severity were common. CONCLUSIONS In patients with polycythemia vera, rusfertide treatment was associated with a mean hematocrit of less than 45% during the 28-week dose-finding period, and the percentage of patients with a response during the 12-week randomized withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist Therapeutics; REVIVE ClinicalTrials.gov number, NCT04057040.) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia.
- Author
-
Peng, Yuanliang, Liang, Long, Zhang, Haihang, Liu, Hong, Zhang, Guanxiong, Sun, Shuming, Guo, Xianfeng, Wang, Yanpeng, Hu, Bin, Liu, Rui, Li, Yanan, Nie, Ling, Zhang, Ji, Ye, Mao, Ginzburg, Yelena Z., Lin, Zhong, Yin, Biao, Chen, Huiyong, and Liu, Jing
- Subjects
- *
ERYTHROPOIESIS , *HEAT shock proteins , *LABORATORY mice , *ANIMAL disease models , *IRON metabolism , *OXYGENASES , *FETAL hemoglobin - Abstract
Summary: Beta‐thalassaemia is an inherited haemoglobin disorder characterised by ineffective erythropoiesis (IE). The detailed pathogenesis of IE remains unclear. In this study, we used single‐cell RNA sequencing (scRNA‐seq) to examine IE in Th3/+ β‐thalassaemic mice. The results showed that the erythroid group was remarkably expanded, and genes involved in biological processes such as iron metabolism, haeme synthesis, protein folding, and response to heat were significantly upregulated from erythroid progenitors to reticulocytes in β‐thalassaemic mice. In particular, we identified a unique cell population close to reticulocytes, named ThReticulocytes, characterised by a high level of heat shock protein 70 (Hsp70) expression and dysregulation of iron metabolism and haeme synthesis signalling. Treatment of β‐thalassaemic mice with the haeme oxygenase inhibitor tin‐mesoporphyrin effectively improved the iron disorder and IE, and the ThReticulocyte population and Hsp70 expression were significantly suppressed. This study revealed in detail the progression of IE at the single‐cell level and possibly provided clues to find therapeutic targets in thalassaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice.
- Author
-
Casu, Carla, Liu, Alison, De Rosa, Gianluca, Low, Audrey, Suzuki, Aae, Sinha, Sayantani, Ginzburg, Yelena Z., Abrams, Charles, Aghajan, Mariam, Guo, Shuling, and Rivella, Stefano
- Subjects
- *
POLYCYTHEMIA vera , *MYELOPROLIFERATIVE neoplasms , *MICE , *THROMBOEMBOLISM , *HEMATOCRIT - Abstract
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm resulting from an acquired driver mutation in the JAK2 gene of hematopoietic stem and progenitor cells resulting in the overproduction of mature erythrocytes and abnormally high hematocrit, in turn leading to thromboembolic complications. Therapeutic phlebotomy is the most common treatment to reduce the hematocrit levels and consequently decrease thromboembolic risk. Here we demonstrate that, by using the iron restrictive properties of the antisense oligonucleotides against Tmprss6 mRNA, we can increase hepcidin to achieve effects equivalent to therapeutic phlebotomy. We provide evidence that this less invasive approach could represent an additional therapeutic tool for the treatment of PV patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
- Author
-
Huihui Li, Tenzin Choesang, Weili Bao, Huiyong Chen, Feola, Maria, Garcia-Santos, Daniel, Jie Li, Shuming Sun, Follenzi, Antonia, Pham, Petra, Jing Liu, Jinghua Zhang, Prem Ponka, Xiuli An, Mohandas, Narla, Fleming, Robert E., Rivella, Stefano, Guiyuan Li, and Ginzburg, Yelena Z.
- Subjects
- *
HEPCIDIN , *ERYTHROPOIESIS , *TRANSFERRIN , *RETICULOCYTES , *LABORATORY mice - Abstract
Iron availability for erythropoiesis and its dysregulation in β-thalassemia are incompletely understood. We previously demonstrated that exogenous apotransferrin leads to more effective erythropoiesis, decreasing erythroferrone (ERFE) and derepressing hepcidin in β-thalassemic mice. Transferrin-bound iron binding to transferrin receptor 1 (TfR1) is essential for cellular iron delivery during erythropoiesis. We hypothesize that apotransferrin's effect is mediated via decreased TfR1 expression and evaluate TfR1 expression in β-thalassemic mice in vivo and in vitro with and without added apotransferrin. Our findings demonstrate that β-thalassemic erythroid precursors overexpress TfR1, an effect that can be reversed by the administration of exogenous apotransferrin. In vitro experiments demonstrate that apotransferrin inhibits TfR1 expression independent of erythropoietin- and iron-related signaling, decreases TfR1 partitioning to reticulocytes during enucleation, and enhances enucleation of defective β-thalassemic erythroid precursors. These findings strongly suggest that overexpressed Tf R1 may play a regulatory role contributing to iron overload and anemia in β-thalassemic mice. To evaluate further, we crossed TfR1+/- mice, themselves exhibiting iron-restricted erythropoiesis with increased hepcidin, with β-thalassemic mice. Resultant double-heterozygote mice demonstrate long-term improvement in ineffective erythropoiesis, hepcidin derepression, and increased erythroid enucleation in relation to β-thalassemic mice. Our data demonstrate for the first time that TfR1+/- haploinsufficiency reverses iron overload specifically in β-thalassemic erythroid precursors. Taken together, decreasing TfR1 expression during β-thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate hepcidin, leading to sustained iron-restricted erythropoiesis and preventing systemic iron overload in β-thalassemic mice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Prolonged red cell storage before transfusion increases extravascular hemolysis.
- Author
-
Rápido, Francesca, Brittenham, Cary M., Bandyopadhyay, Sheila, La Carpia, Francesca, L'Acqua, Camilla, McMahon, Donald j., Rebbaa, Abdelhadi, Wojczyk, Boguslaw S., Netterwald, Jane, Wang, Hangli, Schwartz, Joseph, Eisenberger, Andrew, Soffing, Mark, Yeh, Randy, Divgi, Chaitanya, Ginzburg, Yelena Z., Shaz, Beth H., Sheth, Sujit, Francis, Richard O., and Spitalnik, Steven L.
- Subjects
- *
ERYTHROCYTES , *HEMOLYSIS & hemolysins , *BLOOD transfusion , *BLOOD collection , *TRANSFERRIN , *ERYTHROCYTE metabolism , *COMPARATIVE studies , *RED blood cell transfusion , *IRON , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *TIME , *EVALUATION research , *RANDOMIZED controlled trials - Abstract
Background: Some countries have limited the maximum allowable storage duration for red cells to 5 weeks before transfusion. In the US, red blood cells can be stored for up to 6 weeks, but randomized trials have not assessed the effects of this final week of storage on clinical outcomes.Methods: Sixty healthy adult volunteers were randomized to a single standard, autologous, leukoreduced, packed red cell transfusion after 1, 2, 3, 4, 5, or 6 weeks of storage (n = 10 per group). 51-Chromium posttransfusion red cell recovery studies were performed and laboratory parameters measured before and at defined times after transfusion.Results: Extravascular hemolysis after transfusion progressively increased with increasing storage time (P < 0.001 for linear trend in the AUC of serum indirect bilirubin and iron levels). Longer storage duration was associated with decreasing posttransfusion red cell recovery (P = 0.002), decreasing elevations in hematocrit (P = 0.02), and increasing serum ferritin (P < 0.0001). After 6 weeks of refrigerated storage, transfusion was followed by increases in AUC for serum iron (P < 0.01), transferrin saturation (P < 0.001), and nontransferrin-bound iron (P < 0.001) as compared with transfusion after 1 to 5 weeks of storage.Conclusions: After 6 weeks of refrigerated storage, transfusion of autologous red cells to healthy human volunteers increased extravascular hemolysis, saturated serum transferrin, and produced circulating nontransferrin-bound iron. These outcomes, associated with increased risks of harm, provide evidence that the maximal allowable red cell storage duration should be reduced to the minimum sustainable by the blood supply, with 35 days as an attainable goal.REGISTRATION. ClinicalTrials.gov NCT02087514.Funding: NIH grant HL115557 and UL1 TR000040. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Altered erythropoiesis and iron metabolism in carriers of thalassemia.
- Author
-
Guimarães, Jacqueline S., Cominal, Juçara G., Silva‐Pinto, Ana Cristina, Olbina, Gordana, Ginzburg, Yelena Z., Nandi, Vijay, Westerman, Mark, Rivella, Stefano, and Souza, Ana Maria
- Subjects
- *
THALASSEMIA , *HEMOGLOBINOPATHY , *SYNDROMES , *HEPCIDIN , *ERYTHROPOIETIN , *IRON metabolism , *ERYTHROPOIESIS - Abstract
The thalassemia syndromes (α- and β-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of α- or β-globin chain production results in impaired red blood cell synthesis, anemia, and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis, and dysfunctional iron metabolism has not been investigated in both α-thalassemia carriers ( ATC) and β-thalassemia carriers ( BTC). Here, we demonstrate that ATC have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, BTC have several hematological parameters significantly different from controls, including increased soluble transferrin receptor and erythropoietin levels. These changes in both groups suggest an altered balance between erythropoiesis and iron metabolism. The index s Tf R/log ferritin and (hepcidin/ferritin)/s Tf R are, respectively, increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we showed in this study, for the first time in the literature, that thalassemia carriers have altered iron metabolism and erythropoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
- Author
-
Dussiot, Michael, Maciel, Thiago T, Fricot, Aurélie, Chartier, Céline, Negre, Olivier, Veiga, Joel, Grapton, Damien, Paubelle, Etienne, Payen, Emmanuel, Beuzard, Yves, Leboulch, Philippe, Ribeil, Jean-Antoine, Arlet, Jean-Benoit, Coté, Francine, Courtois, Geneviève, Ginzburg, Yelena Z, Daniel, Thomas O, Chopra, Rajesh, Sung, Victoria, and Hermine, Olivier
- Subjects
- *
ACTIVIN receptors , *ERYTHROPOIESIS , *THALASSEMIA , *PATHOLOGICAL physiology , *ERYTHROCYTE membranes , *CYTOKINES , *GLOBIN - Abstract
The pathophysiology of ineffective erythropoiesis in β-thalassemia is poorly understood. We report that RAP-011, an activin receptor IIA (ActRIIA) ligand trap, improved ineffective erythropoiesis, corrected anemia and limited iron overload in a mouse model of β-thalassemia intermedia. Expression of growth differentiation factor 11 (GDF11), an ActRIIA ligand, was increased in splenic erythroblasts from thalassemic mice and in erythroblasts and sera from subjects with β-thalassemia. Inactivation of GDF11 decreased oxidative stress and the amount of α-globin membrane precipitates, resulting in increased terminal erythroid differentiation. Abnormal GDF11 expression was dependent on reactive oxygen species, suggesting the existence of an autocrine amplification loop in β-thalassemia. GDF11 inactivation also corrected the abnormal ratio of immature/mature erythroblasts by inducing apoptosis of immature erythroblasts through the Fas-Fas ligand pathway. Taken together, these observations suggest that ActRIIA ligand traps may have therapeutic relevance in β-thalassemia by suppressing the deleterious effects of GDF11, a cytokine which blocks terminal erythroid maturation through an autocrine amplification loop involving oxidative stress and α-globin precipitation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron.
- Author
-
Hod, Eldad A., Brittenham, Gary M., Billote, Genia B., Francis, Richard O., Ginzburg, Yelena Z., Hendrickson, Jeanne E., Jhang, Jeffrey, Schwartz, Joseph, Sharma, Shruti, Sheth, Sujit, Sireci, Anthony N., Stephens, Hannah L., Stotler, Brie A., Wojczyk, Boguslaw S., Zimring, James C., and Spitalnik, Steven L.
- Subjects
- *
BLOOD transfusion , *BLOOD cells , *HEMOLYSIS & hemolysins , *TRANSFERRIN , *CARRIER proteins - Abstract
Transfusions of RBCs stored for longer durations are associated with adverse effects in hospitalized patients. We prospectively studied 14 healthy human volunteers who donated standard leuko-reduced, double RBC units. One unit was autologously transfused "fresh" (3-7 days of storage), and the other "older" unit was transfused after 40 to 42 days of storage. Of the routine laboratory parameters measured at defined times surrounding transfusion, significant differences between fresh and older transfusions were only observed in iron parameters and markers of extravascular hemolysis. Compared with fresh RBCs, mean serum total bilirubin increased by 0.55 mg/dL at 4 hours after transfusion of older RBCs (P = .0003), without significant changes in haptoglobin or lactate dehydrogenase. In addition, only after the older transfusion, transferrin saturation increased progressively over 4 hours to a mean of 64%, and non-transferrin-bound iron appeared, reaching a mean of 3.2μM. The increased concentrations of non-transferrin-bound iron correlated with enhanced proliferation in vitro of a pathogenic strain of Escherichia coli (r = 0.94, P = .002). Therefore, circulating non-transferrin-bound iron derived from rapid clearance of transfused, older stored RBCs may enhance transfusion-related complications, such as infection. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. Transferrin therapy ameliorates disease in β-thalassemic mice.
- Author
-
Huihui Li, Rybicki, Anne C., Suzuka, Sandra M., von Bonsdorff, Leni, Breuer, William, Hall, Charles B., Cabantchik, Z. Ioav, Bouhassira, Eric E., Fabry, Mary E., and Ginzburg, Yelena Z.
- Subjects
- *
TRANSFERRIN , *THALASSEMIA treatment , *REGULATION of erythropoiesis , *ANEMIA , *IRON metabolism , *LABORATORY mice , *PHENOTYPES - Abstract
Individuals with β-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in β-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbbth1/th1 mice, an experimental model of β-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human β-thalassemia. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
15. Decreased hepcidin expression in murine ß-thalassemia is associated with suppression of Bmp/Smad signaling.
- Author
-
Parrow, Nermi L., Gardenghi, Sara, Ramos, Pedro, Casu, Carla, Grady, Robert W., Anderson, Erik R., Shah, Yatrik M., Li, Huihui, Ginzburg, Yelena Z., Fleming, Robert E., and Rivella, Stefano
- Subjects
- *
GENETICS of thalassemia , *HEPCIDIN , *BONE morphogenetic proteins , *HEMOGLOBINS , *ERYTHROPOIESIS , *ERYTHROCYTE membranes - Abstract
The article discusses a study on the association of decreased hepcidin expression in murine β-thalassemia with the suppression of bone morphogenetic protein (Bmp) and Smad signaling. It informs that β-thalassemia is a genetic disorder of hemoglobin production in which ineffective erythropoiesis and anemia takes place. It also informs that different erythroid signals regulate hepcidin in normal and ineffective erythropoiesis.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.